Korea Korea is a highly developed and extraordinarily fast-moving market; you simply cannot afford to lag behind Marc Franck, Managing Director of Zuellig Pharma Korea, explains why Korea has become one of the company’s most strategic markets, driven by clinical trials, biologics and advanced logistics. He discusses investments in automation, the…
Japan Patients in Japan deserve the same access to innovative treatments that patients in other markets have. Accelerating that access is what drives us Noriyuki Takai, CEO of EPS Corporation, outlines the CRO’s mission to help address Japan’s drug lag and drug loss by supporting faster access to innovative medicines. He…
Germany Germany remains one of Europe’s most important pharmaceutical markets, combining scientific excellence, strong clinical research capabilities, and early access to innovation. Yet as breakthrough therapies become more sophisticated and global competition for investment intensifies, maintaining that position will require more than scientific strength alone. Urs Voegeli, Managing Director of Johnson…
Germany Scientific breakthroughs are redefining what is possible in cancer care, yet the true test lies in translating discovery into meaningful and lasting patient benefit. Michael Baumann reflects on how the DKFZ is helping shape Germany’s evolving oncology ecosystem through national research networks, precision medicine, clinical trial infrastructure, and a renewed…
Taiwan Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through the state-backed TSMC (Taiwan Semiconductor Manufacturing Company), the island functions as the world’s foundry, manufacturing the advanced chips designed by…
Japan Hideyasu Matsuda and Toru Fujieda of the Japan CRO Association argue that, thanks to an updated regulatory framework, Japan is becoming one of the most competitive and operationally attractive clinical development destinations in the world. Japan is an attractive clinical trial destination from a cost, quality, and speed perspective…
Korea Seong-Wook Lee, CEO and founder of Rznomics, has spent more than two decades advancing trans-splicing ribozyme (TSR) technology as a novel RNA editing platform. After nearly 20 years in academia, he founded Rznomics to translate the approach into therapies for genetic and intractable diseases. With FDA-cleared clinical programmes, strategic partnerships,…
Europe As the European Medicines Agency navigates the most significant expansion of its mandate in a generation, Executive Director Emer Cooke highlights how the regulator is further strengthening its role across the full lifecycle of medicines. Cooke sets out how EMA is enhancing its engagement from early developer support and clinical…
Germany Germany’s Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute for Drugs and Medical Devices (BfArM) outline how the Act attempts to revitalise clinical research in Germany, balancing faster procedures…
Korea Kwunho Jeong, CEO of JNPMEDI, is building an integrated clinical development platform that combines proprietary software, CRO services, and biotech investment to strengthen Asia’s drug development ecosystem. A former consultant and fintech executive, he views clinical trials as fundamentally a data management challenge. Through AI, blockchain-based data integrity, and strategic…
Europe For years, Europe’s pharmaceutical sector has warned about declining competitiveness. Today, according to Nathalie Moll, Director General of EFPIA, that concern has evolved into something far more urgent. As the US and China accelerate their industrial and innovation strategies, Europe finds itself at a critical crossroads where decisions around regulation,…
APAC Ken Lee, Managing Director for Asia Pacific Clinical Business at Syneos Health, draws on a 20-year career across pharma, medicine, and CROs in Europe and Asia. He highlights Asia Pacific’s shift into a global clinical development hub, the rise of Greater China as a leading source of innovation, with mainland…
See our Cookie Privacy Policy Here
